A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam.
Sustained-release (SR) alprazolam may facilitate compliance with oral benzodiazepine treatment of panic disorders that currently requires doses administered three or four times daily. To compare the pharmacokinetic, psychomotor performance, and subjective effects of alprazolam SR (1.5 mg), bromazepam (3 mg taken three times daily), and lorazepam (1 mg taken three times daily), 13 male volunteers (aged 20-45 years) randomly received on four separate occasions one of these medications or placebo. Once before and 11 times after drug administration, the subjects were tested using psychomotor performance tests (manual tracking and digit-symbol substitution test [DSST]) and computerized questionnaires (such as the Tufts University Benzodiazepine Scale [TUBS], the Addiction Research Center Inventory, and the visual analog scales) to determine the subjective effects of the drugs. Blood samples for the determination of the plasma levels of the drugs were collected before and 17 times after the drug was administered. A peak plateau of plasma alprazolam began approximately 6 hours after the dose, which was later than the initial peaks for lorazepam and bromazepam (1-2 hours after the dose). Once this plateau had begun, alprazolam SR sustained that concentration better than did the other two formulations. Of the 10 measures on which the response averaged for the first 14 hours differed among drugs (p < 0.05), bromazepam differed from placebo on two measures, lorazepam on four (including DSST Performance and TUBS Sedation), and alprazolam SR on nine (including all four affected by lorazepam). Lorazepam and alprazolam, but not bromazepam, produced significantly more sedation than placebo. The doses of the three drugs were not equipotent in sedation and mood effects. None of the drugs tested differed from placebo on measures relevant to abuse liability.
Busto
U E
UE
Centre for Addiction and Mental Health, Toronto, Ontario, Canada. usoabusto@camh.net
Kaplan
H L
HL
Wright
C E
CE
Gomez-Mancilla
B
B
Zawertailo
L
L
Greenblatt
D J
DJ
Sellers
E M
EM
D000328:Adult; D000339:Affect / Q000187:drug effects / Q000502:physiology; D000525:Alprazolam / Q000097:blood* / Q000494:pharmacology; D014151:Anti-Anxiety Agents / Q000097:blood* / Q000494:pharmacology; D001960:Bromazepam / Q000097:blood* / Q000494:pharmacology; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D006801:Humans; D016015:Logistic Models; D008140:Lorazepam / Q000097:blood* / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology
D014151:Anti-Anxiety Agents; D003692:Delayed-Action Preparations; D008140:Lorazepam; D001960:Bromazepam; D000525:Alprazolam